Evaxion Biotech A/S (EVAX) experienced an increase of 11.8% in the premarket today after the company announced the Publication of Clinical Data of EVX-01. However, the last trading session concluded at $3.22 with a decrease of 9.3%.
Publication of Clinical Data of EVX-01 – All About it
On 26th January 2022, EVAX announced that the open-access journal OncoImmunology recently published an article on therapy with EVX-01 in patients with metastatic melanoma. The results of the study’s five participants showed that EVX-01 is safe and offers promising early signs of clinically relevant anticancer efficacy. In a clinical context where patients were receiving standard immune therapy, data showed that EVX-01 was capable of triggering T-cell responses.
The results showed that anti-PD-1 medication combined with anti-tumor treatment had an anticancer impact. Furthermore, in a planned Phase 2b research, Evaxion will assess the efficacy and safety of EVX-01 in combination with KEYTRUDA (pembrolizumab). It is an anti-PD1 medication, in approximately 100 persons with unresectable or metastatic melanoma. The main objective will be the overall response.
What’s Next?
Neoantigen-based personalized immunotherapy is a promising cancer treatment strategy. PIONEER’s great promise in producing completely tailored immunotherapies to improve therapy for patients with melanoma. Last but not the least, the company is thrilled to have the funds to pursue EVX-01’s potential in the new Phase 2b trial, which EVAX intends to begin in Q2 2022 in conjunction with Merck.
Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 – Latest News by EVAX
On 18th January 2022, EVAX reported that Australia Therapeutic Goods Administration has approved the start of a Phase 2b trial. The approval of the Phase 2b study of the main medicine is a major step forward for Evaxion. Data from the Phase 1/2a trial suggest that EVX-01 could significantly enhance the therapy landscape for melanoma. Last but not the least, combining EVX-01 with checkpoint inhibitors like KEYTRUDA could provide further advantages.
